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Hypertriglyceridaemia-induced
pancreatitis prompted by acute
corticosteroid treatment: caution for
clinicians
We report two novel cases of hypertriglyceridaemia-
induced pancreatitis induced by corticosteroid taper.
Both patients had known dyslipidaemias and were later
referred to the University of Michigan Lipid Manage-
ment Clinic unaware of the risks of corticosteroids in
their condition.1 These cases highlight the need to be
cognisant that even short-term corticosteroids can pre-
cipitate hypertriglyceridaemia-induced pancreatitis in
susceptible individuals.
Characteristics of the two patients are summarised in
Table 1. Patient 1 is a 41-year-old woman with underlying
type-IV hyperlipidaemia who presented to the emergency
department for urticaria after poison oak exposure and was
discharged on a 10-day course of prednisone (60 mg × 1 d,
40 mg × 5 d and 20 mg × 1 d). Four days after beginning
her corticosteroid taper, shewas hospitalised for acute-onset
abdominal pain. Triglycerides (49.0 mmol/L) and lipase
(7.45 μkat/L) were elevated, and computed tomography of
the abdomen/pelvis confirmed acute pancreatitis. She
denied recent illness or changes in diet, alcohol, medications
or blood glucose. Triglycerides immediately prior to treat-
ment were unknown; her most recent triglycerides were
2.88 mmol/L on gemfibrozil 600 mg twice daily, measured
13 days prior to her admission to the hospital. Neither the
patient nor her inpatient team realised the trigger of her
pancreatitis until a retrospective chart review in lipid clinic
follow-up severalmonths later.
Patient 2 is a 54-year-old woman with a history of
type-V hyperlipidaemia and two previous episodes of
hypertriglyceridaemia-induced pancreatitis, beginning at
age 47. She developed a chronic obstructive pulmonary
disease exacerbation and was prescribed a 7-day course of
prednisone 50 mg daily. While completing her corticoste-
roid burst treatment (exact date of prednisone prescrip-
tion unknown), she developed acute-onset abdominal
pain and presented to the emergency department, where
she had elevated levels of amylase (15.2 μkat/L), lipase
(46.1 μkat/L) and triglycerides (72.4 mmol/L). Triglycer-
ide levels from 2 months prior to her admission to the
hospital were 7.96 mmol/L on fenofibrate nanocrystals
145 mg once daily. She endorsed recent decreased oral
intake, but otherwise denied any changes in alcohol,
medications or blood glucose. No linkage between corti-
costeroids and hypertriglyceridaemia-induced pancreatitis
was considered by her inpatient team.
Differential diagnosis for chylomicron syndrome pre-
cipitation in patients with underlying dyslipidaemias
include poor diet and/or fat intake, alcohol use, non-
compliance with medications, pregnancy and/or wors-
ening diabetes control, systemic oestrogen use, and
Table 1 Baseline characteristics and testing results on presentation for
acute pancreatitis







BMI (kg/m2) 27.9 28.5
Frederickson
phenotype

























Urticarial rash COPD flare
Amylase (μkat/L) – 15.2




CT scan findings Acute uncomplicated
pancreatitis
Not documented
†Documented within 1 month prior to their acute pancreatitis episode.
‡Neither patient was on other lipid-altering medications (e.g. statins,
fish oils) at the time of their acute pancreatitis episode. BID, twice a
day; BMI, body mass index; COPD, chronic obstructive pulmonary dis-
ease; DM, diabetes mellitus type 2, q-day, once daily; OCP, oral contra-
ceptive pills; PCOS, polycystic ovary syndrome.
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rarely, hypothyroidism or nephrotic syndrome. As
noted above, both patients denied these factors as pre-
cipitants of their acutely elevated triglyceride levels and
resulting pancreatitis. Calculation of the Naranjo
Adverse Drug Reaction (ADR) Probability Scale2
resulted in a score of 5 (Supporting Information Appen-
dix S1), indicating a ‘probable’ ADR due to corticoste-
roid use due to the reasonable temporal sequence and
lack of alternative reasonable causes of pancreatitis. We
note that although it is ‘probable’ by the Naranjo scale
that corticosteroids caused acute pancreatitis in these
two patients, this score is artificially low due to the lack
of: (i) prior conclusive case reports in the dyslipidaemic
population; (ii) trials of prednisone discontinuation/
dose reduction/re-administration; (iii) antagonist or
placebo administration; and (iv) prednisone blood level
measurement.
Studies of patients without known dyslipidaemias note
an increase in triglyceride levels with chronic corticoste-
roid use. Of note, triglyceride levels on average were
<2 mmol/L,3 making corticosteroid-induced pancreatitis
unlikely in a non-dyslipidaemic population.4 In contrast,
the lipid-altering effects of corticosteroids in patients
with baseline hypertriglyceridaemia are poorly
described. Despite the theoretical linkage, we are
unaware of prior reports of a brief course of oral cortico-
steroids being implicated as the sole trigger of
hypertriglyceridaemia-induced pancreatitis, except in
chemotherapy patients.1 Unfortunately, neither our
patients nor their healthcare providers realised recent
corticosteroid usage was a potential trigger for pancreati-
tis. We acknowledge that our diagnoses were made by
retrospective histories/chart reviews; however, the tem-
poral course of events strongly support our conclusions,
as noted by a Naranjo scale of 5, indicating a ‘probable’
ADR despite a likely underestimated score due to
numerous ‘do not know’ responses.
These cases show that a short-term course of oral
corticosteroids has the potential to trigger
hypertriglyceridaemia-induced pancreatitis in susceptible
patients. While no evidence-based algorithm exists, sev-
eral prudent recommendations can be made. Foremost,
hyperlipidaemic patients should be educated about the
risks. If treatment is required, providers should obtain
baseline triglyceride and glucose levels, control underly-
ing factors (e.g. diet, alcohol and diabetes), reduce/-
discontinue other offending medications (e.g. oral
oestrogens), and carefully monitor triglycerides. If triglyc-
erides increase >11 mmol/L, discontinuation of oral corti-
costeroids should be strongly considered.5 The benefits of
starting/intensifying triglyceride-lowering medications
(e.g. fibrates, eicosapentaenoic acid/docosahexaenoic
acid) before/during therapy and/or prophylactic apheresis
in severe cases remain unknown. Finally, we recommend
against prescribing corticosteroids if baseline triglycerides
are >5.5 mmol/L,5 unless required for a life-threatening
illness. In conclusion, these cases highlight the importance
that healthcare providers and patients alike be aware of
the potential dangers of oral corticosteroid treatment
among individuals with dyslipidaemias.
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